A Peek Into The Market Before The Trading Starts
Pre-open movers US stock futures are higher this morning, as investors are awaiting consumer credit data. Futures for the Dow Jones Industrial Average surged 33 points to 14,939.00 and S&P 500 index futures rose 2.10 points to 1,615.50. Nasdaq 100 futures gained 6 points to 2,953.50.
A Peek Into Global Markets European markets were higher today. The STOXX Europe 600 Index rose 0.35%, London's FTSE 100 index gained 0.46%, French CAC 40 Index gained 0.57% and German DAX 30 index rose 0.88%.
Asian markets ended higher, with Japan's Nikkei Stock Average jumping 3.55%, China's Shanghai Composite surging 0.20% and Australia's S&P/ASX 200 index dropping 0.22%. Hong Kong's Hang Seng Index rose 0.58% and India's Sensex gained 1.09%.
Broker Recommendation Analysts at Goldman Sachs downgraded American International Group (NYSE: AIG) from “buy” to “neutral.” The target price for American International Group is set to $46.
AIG's shares closed at $45.48 yesterday.
- Fuel Tech (NASDAQ: FTEK) today announced it received three air pollution control contracts. To read the full news, click here.
- Acacia Research Corporation (NASDAQ: ACTG) announced today that its Unified Messaging Solutions LLC subsidiary has entered into a license and settlement agreement with Capital One Financial (NYSE: COF) and Ing Direct. To read the full news, click here.
- Dell (NASDAQ: DELL) today announced the acquisition of Enstratius, an award-winning enterprise cloud-management software and services provider that delivers single and multi-cloud management capabilities. To read the full news, click here.
- Pluristem Therapeutics (NASDAQ: PSTI) announced today that it has identified its first clinical indication in the hematology field for its Placental eXpanded (PLX) RAD cells for the enhancement of the engraftment of Hematopoietic Stem Cells (HSC) in patients experiencing a delay or failure of their bone marrow transplant (BMT). To read the full news, click here.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.